medwireNews: The CDK4/6 inhibitor abemaciclib has received US FDA approval for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

Abemaciclib 150 mg twice daily may now be given alongside an aromatase inhibitor as the initial endocrine therapy for this patient population. The decision follows data from the MONARCH 3 clinical trial, first reported at the ESMO 2017 Congress.